BioLife Solutions, Inc. (BLFS) fair value analysis
Nasdaq · Updated 2026-10-19
BLFS price how computed
Valuation status
Awaiting full valuationBLFS's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once BLFS's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $38.61
- Sector
- Healthcare
- 12-month range
- $18.15–$39.22
- Market cap
- $1.89B
- From 52-week high
- -1.6%
- Shares outstanding
- 48.9M
- Rank in Healthcare by quality score
- #111 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
BioLife Solutions, Inc. is a healthcare company that develops and manufactures biopreservation equipment and related consumables used to preserve cellular and tissue-based products for medical applications. The company operates primarily in the United States and serves customers in the regenerative medicine, cell therapy, and organ transplantation industries.
BLFS currently ranks #111 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.89B
- P/E (trailing)
- 241x
- Revenue (TTM)
- $103M
- Net margin
- 49.1%
- EPS (TTM)
- $0.16
- Gross margin
- 64.2%
- Debt / equity
- 0.04
- Revenue growth (3-yr avg)
- 6.9%
- Shares outstanding
- 48.9M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 61 · neutral
- 50-day average
- $36.87
- 200-day average
- $27.23
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+500.0%)
2026-03 ▲ beat (+100.0%)
2025-12 ▲ beat (+300.0%)
2025-09 ▲ beat (+454.0%)
2025-06 ▼ miss (-1550.0%)
2025-03 ▲ beat (+200.0%)
2024-12 ▲ beat (+71.8%)
2024-09 ▲ beat (+60.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 1 buy · 8 hold · 0 sell (9 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $31
- Target vs last price
- -19.7%
What our data shows for BLFS
- Shares are trading in the upper third of their 12-month price range of $18.15–$39.22.
- The 14-day relative strength index sits at a neutral 61.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BLFS's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent BLFS news
TickrTrends' derived news-sentiment signal for BLFS is currently leaning positive, computed from recent coverage.
- BioLife Solutions Inc (BLFS) Shares Surge 3.5% -- What GF Score of 67 Tells Investors (gurufocus.com, 2026-10-20)
- A Look at BioLife Solutions Inc (BLFS) After 3.5% Gain -- GF Value $27.60 vs Price $38.61 (gurufocus.com, 2026-10-13)
- Repligen Completes Acquisition of BioLife Solutions (manilatimes.net, 2026-10-06)
More BLFS news
- BioLife Solutions, Inc. Extraordinary Shareholders Meeting Transcript (gurufocus.com, 2026-10-05)
What people are saying
Follow the BLFS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' quality grade for BLFS declined from A to C this week, reflecting a deterioration in the derived indicators used to assess the company's operational and financial metrics. The stock remains under awaiting full valuation status, indicating that comprehensive valuation analysis has not yet been completed for this healthcare sector company.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BLFS stock undervalued?
BLFS's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is BLFS's TickrTrends verdict?
BLFS is currently marked 'Awaiting full valuation' - a verdict publishes automatically once BLFS's own trailing P/E history validates under our standards.
How does BLFS compare to other Healthcare stocks?
BLFS ranks #111 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BLFS overbought or oversold?
BLFS's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does BLFS usually beat earnings estimates?
Over its last 8 reported quarters BLFS beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BLFS?
Of 9 analysts covering BLFS, 1 rate it a buy, 8 a hold and 0 a sell - hold-leaning, with a consensus price target of $31 (-19.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.